The safety of brodalumab for the treatment of psoriasis

References

• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029–1072.
   PubMed Web of Science ®Google Scholar
• Kleyn CE, Talbot PS, Mehta NN, et al. Psoriasis and mental health workshop report: exploring the links between psychosocial factors, psoriasis, neuroinflammation and cardiovascular disease risk. Acta Derm Venereol. 2020;100(1):adv00020.
   PubMedGoogle Scholar
• Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133:17–26.
   PubMed Web of Science ®Google Scholar
• Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009;9:556–567.
   PubMed Web of Science ®Google Scholar
• Malakouti M, Brown GE, Wang E, et al. The role of IL-17 in psoriasis. J Dermatolog Treat. 2015;26:41–44.
   PubMed Web of Science ®Google Scholar
• Papp KA, Merola JF, Gottlieb AB, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018;79:277–286.e10.
   PubMed Web of Science ®Google Scholar
• Johnston A, Fritz Y, Dawes SM, et al. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol. 2013;190:2252–2262.
   PubMed Web of Science ®Google Scholar
• Monin L, Gaffen SL. Interleukin 17 family cytokines: signaling mechanisms, biological activities, and therapeutic implications. Cold Spring Harb Perspect Biol. 2018;10:a028522.
   PubMed Web of Science ®Google Scholar
• Bagel J, Lebwohl M, Israel RJ, et al. Immunogenicity and skin clearance recapture in clinical studies of brodalumab. J Am Acad Dermatol. 2020;82(2):344–351.
   Web of Science ®Google Scholar
• Center for Drug Evaluation and Research Application. Number: 761032Orig1s000. Clinical pharmacology and biopharmaceuticals review(s) [Internet]. [cited 2019 Dec 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761032Orig1s000ClinPharmR.pdf.
   Google Scholar
• Kyntheum: EPAR - product information. [Internet]. [cited 2019 Dec 7]. Available from: https://www.ema.europa.eu/en/documents/product-information/kyntheum-epar-product-information_es.pdf.
   Google Scholar
• Puig L, Lebwohl M, Bachelez H, et al. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial. J Am Acad Dermatol. 2020;82(2):352–359.
   PubMed Web of Science ®Google Scholar
• Menter A, Sobell J, Silverberg J. Long-term efficacy of brodalumab for the treatment of moderate-to-severe psoriasis: data from a pivotal phase 3 clinical trial. Winter Clinical Dermatology Conference; Jan 12-17; Hawaii; 2018. Abstract 258. SKIN The Journal of Cutaneous Medicine [Internet]. [cited 2019 Nov 23]. Available from: https://jofskin.org/index.php/skin/article/view/253.
   Google Scholar
• Papp K, Leonardi C, Menter A, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol. 2014;71:1183–1190.e3.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Blauvelt A, Menter A, et al. Efficacy, safety, and patient-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with brodalumab for 5 years in a long-term, open-label, phase II study. Am J Clin Dermatol. 2019;20:863–871.
   PubMed Web of Science ®Google Scholar
• Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175:273–286.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373:1318–1328.
   PubMed Web of Science ®Google Scholar
• Beck KM, Koo J. Brodalumab for the treatment of plaque psoriasis: up-to-date. Expert Opin Biol Ther. 2019;19:287–292.
   PubMed Web of Science ®Google Scholar
• Sawyer LM, Cornic L, Levin LÅ, et al. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. J Eur Acad Dermatol Venereol. 2019;33:355–366.
   PubMed Web of Science ®Google Scholar
• Papp KA, Gordon KB, Langley RG, et al. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br J Dermatol. 2018;179:320–328.
   PubMed Web of Science ®Google Scholar
• Langley RG, Armstrong AW, Lebwohl MG, et al. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials. Br J Dermatol. 2019;180:306–314.
   PubMed Web of Science ®Google Scholar
• Kimmel G, Chima M, Kim HJ, et al. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed. J Am Acad Dermatol. 2019;81:857–859.
   PubMed Web of Science ®Google Scholar
• Gasslitter I, Kirsten N, Augustin M, et al. Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study. Arch Dermatol Res. 2019;311:421–424.
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Nakagawa H, Kubo Y, et al. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176:741–751.
   PubMed Web of Science ®Google Scholar
• Nakao M, Asano Y, Kamata M, et al. Successful treatment of palmoplantar pustular psoriasis with brodalumab. Eur J Dermatol. 2018;28:538–539.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014;370:2295–2306.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Geat D, Pizzolato M, et al. State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis. Curr Opin Pharmacol. 2019;46:90–99.
   PubMed Web of Science ®Google Scholar
• Attia A, Abushouk AI, Ahmed H, et al. Safety and efficacy of brodalumab for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis. Clin Drug Investig. 2017;37:439–451.
   PubMed Web of Science ®Google Scholar
• Ly K, Smith MP, Thibodeaux Q, et al. Anti IL-17 in psoriasis. Expert Rev Clin Immunol. 2019;15:1185–1194.
   PubMed Web of Science ®Google Scholar
• Wcislo-Dziadecka D, Kazmierczak A, Grabarek B, et al. Are new variants of psoriasis therapy (IL-17 inhibitors) safe? Int. J Dermatol. 2019;58(12):1360–1365.
   Web of Science ®Google Scholar
• Di Lernia V, Goldust M. An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly. Expert Opin Biol Ther. 2018;18:897–903.
   PubMed Web of Science ®Google Scholar
• Hsu S, Green LJ, Lebwohl MG, et al. Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials. Br J Dermatol. 2019 Jul 5. DOI:10.1111/bjd.18327. Epub ahead of print.
   Google Scholar
• Saunte DM, Mrowietz U, Puig L, et al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol. 2017;177:47–62.
   PubMed Web of Science ®Google Scholar
• Wu KK, Lee MP, Lee EB, et al. Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions. J Dermatolog Treat. 2019;22:1–7.
   Google Scholar
• Veldhoen M. Interleukin 17 is a chief orchestrator of immunity. Nat Immunol. 2017;18:612–621.
   PubMed Web of Science ®Google Scholar
• Hohenberger M, Cardwell LA, Oussedik E, et al. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat. 2018;29:13–18.
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan B, Vermeire S, et al. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe crohn’s disease. Am J Gastroenterol. 2016;111:1599–1607.
   PubMed Web of Science ®Google Scholar
• Whitlock SM, Enos CW, Armstrong AW, et al. Management of psoriasis in patients with inflammatory bowel disease: from the medical board of the national psoriasis foundation. J Am Acad Dermatol. 2018;78:383–394.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Papp KA, Marangell LB, et al. Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials. J Am Acad Dermatol. 2018;78:81–89.e5.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Romanelli M, Saraceno R, et al. No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents. Expert Opin Drug Saf. 2016;15:1653–1659.
   PubMed Web of Science ®Google Scholar
• Rungapiromnan W, Yiu ZZN, Warren RB, et al. Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2017;176:890–901.
   PubMed Web of Science ®Google Scholar
• Sadik CD, Thieme M, Zillikens D, et al. First emergence of pyoderma gangraenosum, palmoplantar pustulosis and sacroiliitis in a psoriasis patient associated with switching from secukinumab to brodalumab. J Eur Acad Dermatol Venereol. 2019;33(11):e406–e407.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Sato K, Takagi A, et al. Brodalumab-induced palmar pustular eruption and joint swelling accompanied by muscle pains in two cases of psoriasis. J Dermatol. 2018;45:e325–e326.
   PubMed Web of Science ®Google Scholar
• Loft ND, Vaengebjerg S, Halling-Sønderby A-S, et al. Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies. J Eur Acad Dermatol Venereol. 2019 Nov 13. DOI:10.111/jdv.16073. Epub ahead of print.
   Google Scholar
• Bai F, Li GG, Liu Q, et al. Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to Severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials. J Immunol Res. 2019;2019:2546161.
   PubMed Web of Science ®Google Scholar
• Foulkes AC, Warren RB. Brodalumab in psoriasis: evidence to date and clinical potential. Drugs Context. 2019;8:212570.
   PubMedGoogle Scholar
• Kim HJ, Lebwohl MG. Biologics and psoriasis: the beat goes on. Dermatol Clin. 2019;37:29–36.
   PubMed Web of Science ®Google Scholar
• Puig L, Thom H, Mollon P, et al. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2017;31:213–220.
   PubMed Web of Science ®Google Scholar
• Strober B, Papp KA, Lebwohl M, et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol. 2016;75:77–82.e7.
   PubMed Web of Science ®Google Scholar
• Levin EC, Gupta R, Brown G, et al. Biologic fatigue in psoriasis. J Dermatolog Treat. 2014;25:78–82.
   PubMed Web of Science ®Google Scholar
• Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30:1148–1158.
   PubMed Web of Science ®Google Scholar
• Warren RB, Smith CH, Yiu ZZN, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the british association of dermatologists biologic interventions register (BADBIR). J Invest Dermatol. 2015;135:2632–2640.
   PubMed Web of Science ®Google Scholar
• Cheuk S, Wikén M, Blomqvist L, et al. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J Immunol. 2014;192:3111–3120.
   PubMed Web of Science ®Google Scholar
• Park CO, Kupper TS. The emerging role of resident memory T cells in protective immunity and inflammatory disease. Nat Med. 2015;21:688–697.
   PubMed Web of Science ®Google Scholar
• Masson Regnault M, Konstantinou M-P, Khemis A, et al. Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients. J Eur Acad Dermatol Venereol. 2017;31:1491–1496.
   PubMed Web of Science ®Google Scholar
• Beurel E, Harrington LE, Jope RS. Inflammatory T helper 17 cells promote depression-like behavior in mice. Biol Psychiatry. 2013;73:622–630.
   PubMed Web of Science ®Google Scholar
• Schmidt C. Suicidal thoughts end Amgen’s blockbuster aspirations for psoriasis drug. Nat Biotechnol. 2015;33:894–895.
   PubMed Web of Science ®Google Scholar